You are here

Electrophysiology & Arrhythmia


The first-ever proteome of the healthy human heart is complete, a team at the Technical University of Munich has reported—thanks to the successful logging of nearly 11,000 proteins and billions of cells.

From pocket-sized electrocardiograms to watches that measure blood glucose levels, the field of medical technology is rapidly evolving. But these innovations, though oftentimes successful, aren’t necessarily living up to what scientists want them to be, according to presenters at the American Heart Association’s Scientific Sessions 2017.

Men are more likely to receive bystander cardiopulmonary resuscitation (CPR) in public locations than women and are more likely to survive cardiac arrest in those situations, according to research presented Nov. 11 at the American Heart Association’s (AHA) scientific sessions in Anaheim, California.

A new left atrial appendage (LAA) closure device can be implanted with a high success rate and slashes the one-year risk of stroke in nonvalvular atrial fibrillation (NVAF) patients, according to the researchers of the device’s pilot trial.

More cardiac arrest victims will survive if emergency medical dispatchers give cardiopulmonary resuscitation (CPR) instructions over the phone and if infants and children receive rescue breaths in addition to chest compressions, according to updated CPR guidelines released Nov. 7 by the American Heart Association (AHA).


Recent Headlines

Octoberfest study suggests association between acute alcohol consumption and cardiac arrhythmias

An analysis conducted at the Munich Octoberfest found that acute alcohol consumption was associated with sinus tachycardia and other cardiac arrhythmias.

Patients with low health literacy may be less aware of their atrial fibrillation diagnosis

After adjusting for sociodemographics, health behaviors and clinical characteristics, patients with atrial fibrillation who had low health literacy were less likely to be aware of their diagnosis, according to an analysis of members from two large health insurance companies.

InfoBionic hires Stuart Long as CEO

Stuart Long, a veteran medical device executive, has been hired as CEO of InfoBionic.

ICDs may decrease all-cause mortality in patients with nonischemic cardiomyopathy

A meta-analysis of four randomized trials found that using primary prevention implantable cardioverter defibrillators (ICDs) decreased all-cause mortality by 25 percent in patients with nonischemic cardiomyopathy.

Only 17 states require at least some schools install AEDs

Although research has shown automated external defibrillators (AEDs) can increase survival after cardiac arrest, only 17 of 50 U.S. states required at least some of their schools install AEDs as of February 2016, according to a database analysis.

Phillips recalls 47,000 units of its HeartStart MRx monitor/defibrillator

Phillips recalled the HeartStart MRx monitor/defibrillator after discovering electrical and battery connection issues that could prevent the device from powering up, charging and delivering an electrical shock therapy.

ACC.17: Digoxin use may increase the risk of death in patients with atrial fibrillation

Patients with atrial fibrillation and at least one additional risk factor for stroke who received digoxin had higher mortality rates compared with those who did not take digoxin, according to an analysis of a randomized trial.

BioSig Technologies agrees to partnership with two Mayo Clinic electrophysiologists

BioSig Technologies announced an agreement to work with two Mayo Clinic cardiac electrophysiologists to develop features and applications for the company’s PURE EP system.

85% of atrial fibrillation patients receive inadequate anticoagulation prior to stroke

Nearly 85 percent of patients with a history of atrial fibrillation who had an acute ischemic stroke did not receive guideline-recommended anticoagulation or had anticoagulation levels that did not fall in the therapeutic range, according to a registry analysis.

Medtronic’s new cardiac monitor receives FDA approval

The U.S. Food and Drug Administration (FDA) approvead Medtronic’s Reveal LINQ Insertable Cardiac Monitor with TruRhythm Detection, designed to accurately identify abnormal heartbeats.